Skip to content

Author

Chen-Yu Wang

We have 2 of 68 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

The third-year results of denosumab sequential therapy trial: An extension of a randomized clinical trial.

BACKGROUND/PURPOSE Denosumab effectively increases bone mineral density (BMD) and reduces fracture risk in osteoporosis patients. Denosumab discontinuation is related with rebound bone loss and increased fracture risk. Zoledronate has been proposed as sequential therapy to mitigate this effect. We investigated the effi...

Hung-Kuan Yen, Ming-Hung Chiang, Shan-Lun Tsao et al. · 2 citations
Nov 2026

Risk of Incident Type 2 Diabetes with Romosozumab Versus Denosumab in Patients with Osteoporosis: A Global Real-World Cohort Study.

Romosozumab was not associated with an increased risk of incident T2D or other diabetes-related outcomes compared with denosumab, and these findings were supported by calendar-year-specific analyses, although residual confounding and differential follow-up warrant cautious interpretation.

C. Farn, I-Ching Chiang, Hung-Kuan Yen et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.